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Abstract
Analysis of serum to detect EGFR (epidermal growth factor receptor) mutations may be an alternative to using
tumor tissue. Scorpion-ARMS was used to detect serum EGFRmutations in the single-arm Japanese JO22903
erlotinib study. Serum EGFR mutations (exon 19 deletions or L858R) were detected in 26.3% of patients
analyzed; agreement between tumor and serum results was 96.2%. As sensitivity was low, further validation of
serum-based EGFR analysis is needed.
Background: Obtaining tumor samples for epidermal growth factor receptor (EGFR) mutation analysis during treat-
ment can be difﬁcult; therefore, serum samples may be a convenient alternative. We analyzed serum EGFR mutations
in the Japanese phase 2 JO22903 study in chemotherapy-naive nonesmall-cell lung cancer patients with tumor EGFR
mutations. Materials and Methods: Serum samples were analyzed by Scorpion-ARMS to detect EGFR mutations
before and after erlotinib administration. Agreement between serum and tumor EGFR mutations and time course
changes of EGFRmutations were evaluated. Results: A total of 95 of 103 patients consented to examination of serum
samples; baseline serum EGFR mutations (exon 19 deletions or L858R) were detected in 25 patients (26.3%). The
agreement rate between tumor and serum samples was 96.2%. Among 65 serum samples taken at 190 days after
treatment initiation, EGFR mutations were detected in 5 patients (7.7%). Of the serum samples taken at progression
(n ¼ 71), EGFR mutations were detected in 16 patients (22.5%). Patients with baseline serum EGFR mutations had a
median progression-free survival of 9.7 months; those without baseline serum mutations had a median progression-
free survival of 15.2 months. Conclusion: The sensitivity of these analyses was not enough to draw ﬁrm conclusions;
however, the results suggest that serum EGFR mutations correlate with disease activity.
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Clinical Lung Cancer January 2016Introduction
Nonesmall-cell lung cancer (NSCLC) remains a signiﬁcant global
health burden, with high mortality and poor prognosis for patients
diagnosed at advanced stage. One treatment option is erlotinib, an
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
(TKI). The efﬁcacy of erlotinib in the second-line setting was initially
shown by the phase 3 BR.21 study.1 In Japanese patients with pre-
viously treated disease, 2 phase 2 studies have also proven the efﬁcacy
and tolerability of erlotinib.2,3 Kubota et al2 showed progression-free
survival (PFS) of 77 days and median overall survival (OS) of1525-7304/ª 2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.cllc.2015.07.001
Figure 1 CONSORT Diagram14.7 months, while Takahashi et al3 reported time to progression of
75 days and median OS of 13.5 months. In the ﬁrst-line EURTAC
study of patients whose tumors harbored EGFR mutations, median
PFS was 9.7 months and median OS was 19.3 months for erlotinib.4
This led to erlotinib becoming the standard treatment for ﬁrst-line
EGFR mutationepositive NSCLC.
The phase 2, single-arm JO22903 study of single-agent erlotinib
was designed to obtain further conﬁrmatory data for erlotinib in the
ﬁrst-line treatment setting for Japanese patients with EGFR muta-
tionepositive NSCLC. The JO22903 primary efﬁcacy results re-
ported median PFS of 11.8 months, a 1-year event-free survival rate
of 50%, and an overall response rate of 78%.5
Conﬁrmation of posttreatment EGFRmutation status is important
to aid selection of optimal subsequent therapy after acquired resis-
tance to erlotinib treatment. However, obtaining tumor samples can
be difﬁcult outside of surgical resection and initial biopsies, as
nonsurgical methods often do not provide sufﬁcient tumor DNA for
analysis after treatment initiation. Therefore, plasma or serum sam-
ples may be more appropriate for further mutation testing in this
setting, although sensitivity of this method must be considered. The
Scorpion-ARMS method is one of the most sensitive methods for
speciﬁc detection of mutations in DNA, as it enables single base
mutations to be detected.6,7 A single base mismatch at the 30 end of
the primer is sufﬁcient for preferential ampliﬁcation of the identically
matched allele, allowing for precise discrimination between closely
related sequences. Previous studies have already suggested the feasi-
bility of using serum DNA to evaluate EGFR mutation status using
the Scorpion-ARMS method in patients treated with geﬁtinib.8,9
This prespeciﬁed analysis measured EGFR mutations in serum
samples before and after administration of erlotinib in the phase 2
JO22903 study compared the data with results from tumor samples
in order to demonstrate a level of agreement and evaluated the time
course changes of EGFR mutation type in serum samples.
Materials and Methods
Study Design
JO22903 was a phase 2, multicenter, open-label, nonrandomized
study conducted at 25 centers in Japan. The detailed study design
has been previously reported.5 Eligible patients had advanced, un-
treated, metastatic (stage IIIB/IV) or relapsed NSCLC, with an
Eastern Cooperative Oncology Group (ECOG) performance status
(PS) of 0 or 1 and tumors harboring conﬁrmed activating mutations
of EGFR (exon 19 deletion or L858R point mutation in exon 21).
All patients provided written informed consent for this analysis.
Patients received oral erlotinib 150 mg per day until disease pro-
gression or unacceptable toxicity. Tumor EGFR mutation testing
was carried out in local or central laboratories; Scorpion-ARMS
methodology was used for testing in the central laboratory, while
PNA LNA PCR-Clamp (42.7%), PCR-Invader (23.3%), Cycleave
(17.5%), high-resolution melting analysis (5.8%), and direct
sequencing (2.9%) were used in local laboratories, as methods that
were used in daily practice at each site were selected. A high degree
of agreement between these testing methodologies was observed.5
Serum Analysis
Serum samples were analyzed using Scorpion-ARMS methodol-
ogy in the central laboratory. Serum was extracted from 3.5 mL ofblood collected at baseline screening, on day 190 of treatment, and
at disease progression (as judged by the investigator). DNA was
extracted from 0.5 mL of serum using the QIAamp DNA MinElute
Virus Spin Kit (Qiagen, UK) as per the manufacturer’s instructions.
EGFR gene mutations in DNA from serum were analyzed by
Scorpion-ARMS using the EGFR RGQ PCR kit or Therascreen
EGFR RGQ PCR kit (Qiagen, UK) as per the manufacturer’s in-
structions. Scorpion-ARMS detected exon 19 deletions, L858R
mutation, T790M mutation, L861Q mutation, G719X mutations,
S768I mutation, and exon 20 insertions. The limits of detection for
each mutation were as follows: exon 19 deletions (1.64%), L858R
(1.26%), T790M (7.02%), L861Q (0.50%), G719X (5.43%),
S768I (1.37%), and exon 20 insertions (2.03%).
This analysis evaluated agreement between EGFR mutations in
serum and tumor tissue at screening and time course changes of
EGFR mutation type in serum samples. The association between
serum mutations and PFS outcomes was also evaluated.
Statistical Analyses
For PFS, which was assessed by investigators, median and 95%
conﬁdence limits were estimated by Kaplan-Meier methodology.
Conﬁdence interval (CI) limit was calculated according to the
Greenwood method.
Results
Patient Population
Between April 8, 2010, and September 6, 2010, a total of 103
patients with conﬁrmed EGFR mutations in tumor tissue were
enrolled (n ¼ 50 with exon 19 deletions, n ¼ 51 with L858R
mutations, n ¼ 2 with L858R þ T790M mutations). Serum EGFR
mutations were determined at screening (n ¼ 95), day 190 of
treatment (n ¼ 65), and at disease progression (n ¼ 71) (Figure 1).
Baseline characteristics are shown in Table 1. Overall, more
female patients than male, more patients with ECOG PS 1 versus 0,
and more patients with stage IV disease were enrolled.Clinical Lung Cancer January 2016 - 25
Table 1 Baseline Characteristics
Variable
Serum EGFR Mutation
Detected
(n [ 25)
Undetected
(n [ 70)
Gender, n (%)
Female 15 (60.0) 50 (71.4)
Male 10 (40.0) 20 (28.6)
Median age, years (range) 63.0 (42-80) 67.0 (36-86)
ECOG PS, n (%)
0 8 (32.0) 37 (52.9)
1 17 (68.0) 33 (47.1)
Smoking Status, n (%)
Current smoker 3 (12.0) 4 (5.7)
Former smoker 12 (48.0) 22 (31.4)
Never smoker 10 (40.0) 44 (62.9)
Stage, n (%)
IIIB 0 (0.0) 4 (5.7)
IV 19 (76.0) 50 (71.4)
Postoperative recurrence 6 (24.0) 16 (22.9)
Abbreviations: ECOG PS ¼ Eastern Cooperative Oncology Group performance status;
EGFR ¼ epidermal growth factor receptor.
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26 -Comparison of EGFR Mutations in Serum and Tumor
Tissue at Baseline Screening
Of the 95 patients with serum samples at baseline screening, 45
were identiﬁed as having exon 19 deletions by tumor sample
analysis, and 50 were identiﬁed as having exon 21 L858R muta-
tions. The detection rate of serum mutations identiﬁed as exon 19
deletions or L858R mutations before erlotinib treatment was 26.3%
overall (25 of 95), with a detection rate of 35.6% for exon 19 de-
letions (16 of 45) and 18.0% for L858R mutations (9 of 50)
(Table 2). One patient had an exon 20 S768I mutation, which is
known as a minor mutation, detected in serum.
The agreement rate between serum and tumor tissue samples was
96.2% for patients whose serum status was detected (25 of 26).
There was a 100% agreement rate between tumor and serum
samples for exon 19 deletions and for exon 21 L858R mutations.
The patient whose mutation status was discordant had target lesion
tumors in the right middle lobe and left upper lobe of the lung and
multiple nontarget lesions in the pleura. In this patient’s sample, a
S768l mutation was detected from the serum sample, but only the
exon 19 deletion was detected from the tumor sample. T790MTable 2 Serum EGFR Mutations Before Erlotinib Treatment
Characteristic No. of Patients
Percentage D
(N Seru
Serum collected 95
EGFR Mutation Detected in Serum 25 26.3
Exon 19 deletion 16 35.6
Exon 21 L858R 9 18.0
Abbreviation: EGFR ¼ epidermal growth factor receptor.
Clinical Lung Cancer January 2016mutation or minor mutations other than S768l were not detected in
any serum samples before erlotinib treatment.
Patients with serum EGFR mutations identiﬁed as exon 19
deletion or L858R mutation at baseline had a lower median age;
there were also fewer patients with ECOG PS 0 and fewer never
smokers than those patients without serum mutations at baseline
(Table 1). Characteristics of patients with serum EGFR mutations
detected at baseline were large number of organs with tumors or
metastases and large tumor size. A total of 7.7% of patients who had
one affected organ had serum EGFR mutations compared with
53.8% of those who had 4 affected organs and 75.0% of those with
6 affected organs (Table 3). The mean number of affected organs
for patients who had serum EGFR mutations was 3.80 (95% CI,
3.27-4.33) compared with 2.54 (95% CI, 2.26-2.82) for patients
without serum EGFR mutations. Mutation detection rates by
affected organ are shown in Supplemental Table 1 in the online
version. A higher mutation detection rate was seen in patients whose
sum of the longest diameter of target lesions was over 74 mm
(40.0%) compared with those whose tumors were less than 26 mm
in diameter (15.0%) (Table 4). The mean sum of the longest
diameter for patients who had serum EGFR mutations was
49.7 mm (95% CI, 40.9-58.5) compared with 68.1 mm (95% CI,
49.9-86.3) for patients without serum EGFR mutations. Median
PFS for patients who had serum EGFR mutations at baseline was
9.7 months (95% CI, 5.5-12.3) compared with 15.2 months (95%
CI, 9.7-17.9) for patients without serum EGFR mutations at
baseline.
Time Course Determination of EGFR Mutations in
Serum
At day 190 of erlotinib treatment, serum EGFR mutations were
detected in only 5 patients (7.7%) out of the 65 with available
samples. The 65 patients whose samples were available at day 190
had nonprogressive disease and were still receiving erlotinib treat-
ment. Of the 5 patients with serum EGFR mutations, 4 patients had
exon 19 deletions, while 1 had an L858R mutation.
At disease progression, serum EGFR mutations were detected in
16 (22.5%) of the 71 patients with available samples. This included
12 (57.1%) of the 21 patients with available samples whose serum
EGFR mutations were detected at baseline. Of the 16 patients, 8
had exon 19 deletions (5 of these patients also had T790M muta-
tions), while 8 had L858R mutations (2 of these patients also had
T790M mutations) (Table 5).
Most of the patients had the same mutation in serum after
treatment with erlotinib compared with baseline screening serum oretection In Serum
m/N Tissue)
Agreement Between Serum and Tissue
(N Tissue/N Serum)
e e
% (25/95) 96.2% (25/26)
% (16/45) 100% (16/16)
% (9/50) 100% (9/9)
Table 3 Mutation Detection Rates in Serum Stratiﬁed by
Number of Organs With Tumors or Metastases
No. of Affected
Organs
No. of
Patients
No. of Patients
With Mutation
Detected
Percentage of
Mutations
Detected
1 13 1 7.7% (1/13)
2 29 2 6.9% (2/29)
3 27 8 29.6% (8/27)
4 13 7 53.8% (7/13)
5 9 4 44.4% (4/9)
6 4 3 75.0% (3/4)
Total 95 25 26.3% (25/95)
Makoto Nishio et altumor samples; however, 2 patients had changed mutations from
L858R mutations at baseline to exon 19 deletions at day 190. One
patient had target lesion tumors in the right upper lobe of the lung
and in the lymph nodes, with brain (multiple lesions), bone
(multiple lesions), and pericardial effusion as nontarget lesions.
Target lesions were decreased with erlotinib treatment (partial
response) but progressed at day 335. Bone and brain metastases as
nontarget lesions did not change during the treatment period, and
pleural effusion as nontarget lesions disappeared; however, new le-
sions were found. The other patient had tumors in the right middle
lobe of the lung and in the lymph nodes as target lesions, with brain
(multiple lesions) and bone (multiple lesions) as nontarget lesions.
Target lesions were decreased (partial response), and brain metas-
tases as nontarget lesions did not change as of day 210; however,
bone metastases as nontarget lesions progressed at day 245, and a
new lesion was found in bone TH3 at day 245.
T790M mutation was detected in serum for 7 patients. Serum
sample collection day for each of these patients was 167, 252, 266,
358, 382, 547, and 609 days after the start of erlotinib, respectively.
Discussion
Obtaining tumor samples can be difﬁcult outside of surgical
resection and initial biopsies, as nonsurgical methods often do not
provide sufﬁcient tumor DNA for analysis after treatment initiation.
Therefore, plasma or serum samples may be more appropriate for
posttreatment EGFR mutation testing if agreement with tumor
samples can be demonstrated.Table 4 Mutation Detection Rate in Serum Stratiﬁed by Tumor
Size at Baseline
Sum of Longest
Diameter (mm)
No. of
Patients
No. of Patients
With Mutation
Detected
Percentage of
Mutations
Detected
<26a 20 3 15.0% (3/20)
26 <41b 27 7 25.9% (7/27)
41 <74c 23 5 21.7% (5/23)
74 25 10 40.0% (10/25)
Total 95 25 26.3% (25/95)
aUpper quartile.
bMedian.
cLower quartile of the baseline population (n ¼ 95).In the JO22903 study, although the agreement rate between
serum and tumor tissue samples at baseline screening was high
(96.2%), detection sensitivity was low (mutation detection rate in
serum samples before initiation of erlotinib treatment was 35.6%
for exon 19 deletions [16 of 45] and 18.0% for L858R mutations
[9 of 50]). The detection rate in serum appeared better for exon 19
deletions compared with L858R mutations; however, the reasons
behind this are unclear. This could be due to the heterogeneous
nature of tumor biology or due to the assay itself. Some reports
suggested that there is a difference in phenotype between L858R
and exon 19 deletion, which could be related to this difference.10,11
Further investigation is needed to optimize this method of mutation
identiﬁcation.
The detection sensitivity in serum has varied among previous
studies. Bai et al12 reported a sensitivity of 81.8% using a dena-
turing high-performance liquid chromatography detection tech-
nique in Chinese patients with advanced NSCLC treated with ﬁrst-
line chemotherapy. Rosell et al13 showed sensitivity of 59.1% using
both direct sequencing and allele-speciﬁc detection techniques in
Spanish patients treated with ﬁrst- or second-line erlotinib. Sensi-
tivity of 75.0% was shown by Kimura et al8 using Scorpion-ARMS
with patients treated with ﬁrst-, second-, or third-line geﬁtinib.
Goto et al9 reported sensitivity of 43.1% using Scorpion-ARMS in a
Japanese NSCLC population treated with ﬁrst-line geﬁtinib. The
reason why this JO22903 analysis showed the lowest sensitivity
among previous studies is unclear. One possibility is that the vari-
ance of sensitivity between studies may be attributed to the different
methods of extraction, detection, and run conditions. Previously,
these studies showed that improvement in detection sensitivity
would be needed for use in daily clinical practice at this time.
Interestingly, Mok et al14 have recently shown promising data using
a new polymerase chain reaction (PCR)-based method optimized
for blood screening in the FASTACT-2 study, in which sensitivity
was 75% and concordance was 88% using the Cobas 4800 blood
test (in development). Overall, these studies concluded that the
detection of EGFR mutations in serum or plasma could be feasible,
and further investigation is warranted.
Characteristics of patients with serum EGFR mutations in pre-
treatment samples were large number of affected organs and large
sum of longest diameter of target lesion. This may be explained by
those patients with an increased tumor burden having more cells or
DNA to leak into the serum as circulating tumor cells, therefore
resulting in more successful detection of mutations as more cells are
present to analyze. This may also explain why a higher mutation
detection rate was seen in patients with ECOG PS 1 compared with
PS 0 (34.0% vs. 17.8%, respectively), as those with PS 1 would
typically have a higher tumor load, therefore shedding more cells
into serum for analysis. Median PFS for patients with serum EGFR
mutations was shorter than for those without serum EGFR muta-
tions. This again could be attributed to these patients having a larger
number of affected organs, as tumor distribution is a critical factor
in progression and survival.
At day 190 of erlotinib treatment, serum EGFR mutations were
detected in only 5 patients, whereas at disease progression serum
EGFR mutations were detected in 16 patients. This could be
explained by the changing tumor burden, as during treatment (day
190) the tumor burden may have decreased from that seen atClinical Lung Cancer January 2016 - 27
Table 5 EGFR Mutations After Erlotinib Treatment in Patients With Detected Mutations in Day 190 and/or PD Serum Samples
Tumor Baseline
EGFR Mutation Serum
Best Overall Response PFS (Days)Baseline Day 190 PD
L858R L858R ea L858R PD 23
L858R L858R e L858R PD 46
L858R L858R e L858R PD 85
L858R L858R e L858R PR 163
19del 19del e 19del þ T790M SD 167
L858R No e L858R PR 175
L858R No 19del L858R þ T790M PR 245
19del 19del 19del 19del þ T790M PR 253
L858R L858R L858R L858R SD 259
19del 19del No 19del PR 297
L858R L858R 19del No SD 334
19del No 19del 19del þ T790M PR 337
L858R L858R No L858R þ T790M PR 375
19del 19del No 19del PR 380
19del 19del No 19del þ T790M PR 547
19del þ G719X 19del No 19del þ T790M PD 585
19del No No 19del PR 714
Abbreviations: EGFR ¼ epidermal growth factor receptor; No ¼ mutation not detected; PD ¼ progressive disease; PFS ¼ progression-free survival; PR ¼ partial response; SD ¼ stable disease.
aA dash indicates no sample was available.
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28 -baseline, therefore resulting in fewer cells leaking into the serum,
leading to a lower mutation detection rate. At disease progression,
when a patient has an increased tumor burden, more cells are present
in the serum again, allowing for a higher mutation detection rate.
Although some previous studies showed the correlations between
clinical characteristics and EGFR mutation status detected from
blood samples,8,9,12-14 no studies have reported a correlation with
tumor burden. Meanwhile, Mok et al14 demonstrated the change of
EGFR mutation status throughout the course of erlotinib treatment
and the detection rate was lower in the middle of treatment than at
baseline or after progression disease, which is consistent with our
data.
The T790M mutation was not detected in any serum samples
before erlotinib treatment, and was only seen in serum samples at
disease progression not at day 190. This may be because this muta-
tion is more prevalent in tumors after initial treatment. T790M cells
are resistant to erlotinib; therefore, during treatment, other cells that
are not resistant are depleted, meaning that T790M cells are enriched
and are more likely to be identiﬁed at this time point. T790M mu-
tation was not detected at disease progression in 3 patients who had
progression disease early (< 100 days) without tumor response,
which suggested that these patients had resistance factor other than
T790M mutation. Oxnard et al15 showed that acquired T790M
mutation has been associated with indolent growth compared with
T790M-negative acquired resistance, which is consistent with the
results of JO22903. These data suggest that the time to onset of
resistance is different depending on the mechanism of resistance. The
T790M mutation is known to have poor sensitivity to EGFR TKIs
and has been suggested as one of the major reasons for EGFR TKI
treatment failure; thus, T790M mutant-selective covalent inhibitors
or other novel agents would be beneﬁcial for patients with theClinical Lung Cancer January 2016acquired T790M mutation. However, EGFR TKIs might still be
effective for some patients with acquired resistance other than
T790M, and EGFR TKI readministration or continuation would be
possible treatment options for those patients. Although the overall
detection sensitivity was only 22.5% (16 of 71) at disease progression,
serum EGFR mutations were able to be detected in 57.1% of patients
whose serum EGFR mutations were detected at baseline. Also, the
T790M mutation was detected at the time of disease progression by
Scorpion-ARMS, which can be used in clinical practice. These data
suggest that serum EGFR mutations monitoring during treatment
may be useful if serum EGFR mutations are detected at baseline. To
obtain useful information for optimal treatment selection in every
patient with EGFR TKI resistance, improved sensitivity methods
with plasma or serum are required.
Most of the patients had the same mutations in serum after
treatment with erlotinib compared with the baseline screening
serum and tumor samples. Two patients had changed mutations;
however, these patients also had multiple metastases. This change in
mutation could be due to the heterogeneous nature of NSCLC
between primary and metastatic tumors; however, the causality of
these mutation changes is not fully understood and could warrant
further investigation.
Conclusion
Detection of EGFR mutations from serum samples provided
insufﬁcient accuracy in this study; this method needs to be
improved in order to obtain further conﬁrmatory results. Mutation-
positive serum samples provided a 96.2% agreement rate with tu-
mor mutation analysis. The data also suggest that the changing time
course of serum EGFR mutations could correlate with disease ac-
tivity. Serum EGFR mutation detection during treatment course
Makoto Nishio et alcould give useful information for subsequent treatment selection,
especially in situations where obtaining tumor samples is difﬁcult;
however, further investigation is needed.
Clinical Practice Points
 Obtaining tumor samples for assessment of EGFR mutation status
can be difﬁcult in some cases; therefore, a less invasive method to
acquire samples for mutation detection would be beneﬁcial.
Blood-based samples (either plasma or serum) have recently been
investigated in a number of studies using various techniques
including Scorpion-ARMS, denaturing high-performance liquid
chromatography, peptide nucleic acidemediated PCR, and digital
droplet PCR. Although detection rates vary between the different
methods, the overall consensus is that blood-based analysis is
feasible.
 The JO22903 study used Scorpion-ARMS technology to assess
EGFR mutations in serum samples in Japanese patients treated
with erlotinib. Baseline serum EGFR mutations were detected
in 25 patients (26.3%). The agreement rate between tumor
and serum samples was 96.2%. Patients with baseline serum
EGFR mutations had median PFS of 9.7 months; those
without baseline serum mutations had median PFS of 15.2
months.
 The sensitivity was low for the detection of EGFR mutations
from serum in JO22903, which highlights that further validation
of the optimal method for blood-based assessment is needed,
including comparing serum versus plasma samples in addition to
different assessment methodologies. The JO22903 results sug-
gested that the changing time course of serum EGFR mutations
could correlate with disease activity. This is an aspect that, once
further validated, could provide an alternative to the Response
Evaluation Criteria in Solid Tumors for assessing disease pro-
gression. Validation of a blood-based assessment method will
allow patients who are currently unable to undergo tissue-based
mutation testing to get tested, resulting in better guidance for
treatment decisions.Acknowledgments
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Supplemental Table 1 Mutation Detection Rates in Serum by Organ With Tumors or Metastases
Affected Organ Patients With Mutation Detected Patients With Mutation Not Detected
Lung (n ¼ 86) 26.7% (23/86) 73.3% (63/86)
Lymph node (n ¼ 56) 37.5% (21/56) 62.5% (35/56)
Pleura (n ¼ 27) 22.2% (6/27) 77.8% (21/27)
Pleural effusion (n ¼ 27) 40.7% (11/27) 59.3% (16/27)
Bone (n ¼ 30) 46.7% (14/30) 53.3% (16/30)
Brain (n ¼ 20) 40.0% (8/20) 60.0% (12/20)
Liver (n ¼ 10) 50.0% (5/10) 50.0% (5/10)
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